IL6 and breast cancer: These findings suggest that ADSC-EVs selectively suppress components of the IL-6/STAT3 signaling axis, particularly downstream targets such as IL-6RST and STAT3, thereby contributing to their inhibitory effects on MCF-7 breast cancer cells.